These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 17274675)
21. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385 [TBL] [Abstract][Full Text] [Related]
22. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs. Sommerville KW; Dutta S; Biton V; Zhang Y; Cloyd JC; Uthman B Clin Drug Investig; 2003; 23(10):661-70. PubMed ID: 17535081 [TBL] [Abstract][Full Text] [Related]
23. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478 [TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970 [TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. Horne RL; Cunanan C J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219 [TBL] [Abstract][Full Text] [Related]
26. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490 [TBL] [Abstract][Full Text] [Related]
27. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Ravindran A; Silverstone P; Lacroix D; van Schaick E; Vermeulen A; Alexander J Clin Pharmacokinet; 2004; 43(11):733-40. PubMed ID: 15301577 [TBL] [Abstract][Full Text] [Related]
28. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032 [TBL] [Abstract][Full Text] [Related]
29. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. Darwish M; Yang R; Tracewell W; Robertson P; Bond M Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074 [TBL] [Abstract][Full Text] [Related]
30. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176 [TBL] [Abstract][Full Text] [Related]
31. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration. Dulac O; Alvarez JC Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218 [TBL] [Abstract][Full Text] [Related]
32. Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. Zakeri-Milani P; Nemati M; Ghanbarzadeh S; Hamishehkar H; Valizadeh H Arzneimittelforschung; 2011; 61(8):439-43. PubMed ID: 21950147 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH; Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Brittain ST; Wheless JW Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125 [TBL] [Abstract][Full Text] [Related]
35. Extended-release formulations for the treatment of epilepsy. Bialer M CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575 [TBL] [Abstract][Full Text] [Related]